These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 39015186)

  • 1. Oral Semaglutide in Type 2 Diabetes: Clinical-Metabolic Outcomes and Quality of Life in Real-World Practice.
    Pantanetti P; Ronconi V; Sguanci M; Palomares SM; Mancin S; Tartaglia FC; Cangelosi G; Petrelli F
    J Clin Med; 2024 Aug; 13(16):. PubMed ID: 39200893
    [No Abstract]   [Full Text] [Related]  

  • 2. Temporal Relationship between HbA1c and Depressive Symptom Trajectories in a Longitudinal Cohort Study: The Mediating Role of Healthy Lifestyles.
    Zeng N; Li C; Mei H; Wu S; Liu C; Wang X; Bao Y
    Brain Sci; 2024 Jul; 14(8):. PubMed ID: 39199473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation.
    Meier JJ
    Front Endocrinol (Lausanne); 2021; 12():645617. PubMed ID: 34248838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice.
    Pantanetti P; Cangelosi G; Alberti S; Di Marco S; Michetti G; Cerasoli G; Di Giacinti M; Coacci S; Francucci N; Petrelli F; Ambrosio G; Grinta R
    Front Endocrinol (Lausanne); 2024; 15():1394506. PubMed ID: 39015186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus.
    Rodríguez Jiménez B; Rodríguez de Vera Gómez P; Belmonte Lomas S; Mesa Díaz ÁM; Caballero Mateos I; Galán I; Morales Portillo C; Martínez-Brocca MA
    Front Endocrinol (Lausanne); 2024; 15():1386542. PubMed ID: 38894744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).
    Caballero Mateos I; García de Lucas MD; Doulatram-Gamgaram VK; Moreno-Moreno P; Jimenez-Millan AI; Botana-López M; Merino-Torres JF; Soto-Gónzalez A; Fernández-García JC; Morales-Portillo C
    Nutrients; 2024 Aug; 16(15):. PubMed ID: 39125424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study.
    Bonora BM; Russo G; Leonetti F; Strazzabosco M; Nollino L; Aimaretti G; Giaccari A; Broglio F; Consoli A; Avogaro A; Fadini GP;
    J Endocrinol Invest; 2024 Jun; 47(6):1395-1403. PubMed ID: 38369592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of semaglutide with risk of suicidal ideation in a real-world cohort.
    Wang W; Volkow ND; Berger NA; Davis PB; Kaelber DC; Xu R
    Nat Med; 2024 Jan; 30(1):168-176. PubMed ID: 38182782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic analysis reveals semaglutide impacts lipogenic protein expression in epididymal adipose tissue of obese mice.
    Zhu R; Chen S
    Front Endocrinol (Lausanne); 2023; 14():1095432. PubMed ID: 37025414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
    Amaro A; Sugimoto D; Wharton S
    Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany.
    Menzen M; Berentzen TL; Catarig AM; Pieperhoff S; Simon J; Jacob S
    Exp Clin Endocrinol Diabetes; 2023 Apr; 131(4):205-215. PubMed ID: 36599459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
    Volpe S; Lisco G; Fanelli M; Racaniello D; Colaianni V; Triggiani D; Donghia R; Crudele L; Rinaldi R; Sabbà C; Triggiani V; De Pergola G; Piazzolla G
    Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
    Kosiborod MN; Bhatta M; Davies M; Deanfield JE; Garvey WT; Khalid U; Kushner R; Rubino DM; Zeuthen N; Verma S
    Diabetes Obes Metab; 2023 Feb; 25(2):468-478. PubMed ID: 36200477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.
    Martins FF; Marinho TS; Cardoso LEM; Barbosa-da-Silva S; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
    Cell Biochem Funct; 2022 Dec; 40(8):903-913. PubMed ID: 36169111
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.